RDFA
IBRX icon

Ritter Daniher Financial Advisory’s ImmunityBio IBRX Stock Holding History

Ritter Daniher Financial Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.9K Hold
3,305
– – ﹤0.01% 330
2026
Q1 		$25.4K Buy
+3,305
New +$22.6K ﹤0.01% 340

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ritter Daniher Financial Advisory's IBRX Position: Q2 2026 in Review

Ritter Daniher Financial Advisory held its ImmunityBio (IBRX) position steady in Q2 2026 at 3,305 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #330.

Ritter Daniher Financial Advisory first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Ritter Daniher Financial Advisory held 3,305 shares of ImmunityBio worth $28.9K as of Q2 2026.
  • Ritter Daniher Financial Advisory left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Ritter Daniher Financial Advisory's portfolio in Q2 2026, its #330 holding.
  • Ritter Daniher Financial Advisory first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Ritter Daniher Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.